#India #New Delhi #Datar Cancer Genetics #Exacta AI #AI-driven cancer care

Datar Cancer Genetics Unveils Exacta AI

In a significant advancement for personalized medicine, Datar Cancer Genetics (DCG) has introduced Exacta AI, a sophisticated AI-driven multi-analysis platform aimed at improving treatment options for cancer patients whose standard therapies have been exhausted. This innovative platform integrates comprehensive tumor analysis with cutting-edge artificial intelligence to decode complex tumor data effectively.

The Power of Multi-Analysis

Exacta AI combines multifaceted data sources, including molecular (NGS DNA + RNA), proteomic, genomic, functional, and clinical insights. By processing real-time laboratory data and melding it with medical knowledge from various sources, it assesses the synergy, interactions, toxicity, and contraindications of cancer medications. These include antibody-drug conjugates (ADCs), checkpoint inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapies, and repurposed drugs.

This state-of-the-art platform can provide oncologists and molecular tumor boards (MTBs) with up to ten evidence-based treatment alternatives, presenting new hope for patients facing refractory or recurrent cancer when standard treatment options are lacking.

A New Era in Cancer Therapy

Dr. Sewanti Limaye, Director of Medical and Precision Oncology at Sir HN Reliance Foundation Hospital, emphasized the transformative nature of Exacta AI during a session of the Datar Advisory Board. She stated, "For too long, we have struggled through fragmented data and various analysis methods without a clear structure. This AI-driven approach enables integrated, evidence-based decision-making that could revolutionize how we personalize cancer treatments."

Dr. Andy Gaya, a clinical oncologist at Cromwell Hospital in London, further remarked, "Exacta AI signifies a paradigm shift in tumor multi-omics analysis and personalized therapy decision-making. This technology allows for unprecedented precision in therapy selection, enhancing treatment outcomes while reducing unnecessary burdens from ineffective therapies."

According to Dr. Darshana Patil, Senior Director of Global Strategy and Medical Affairs, Exacta AI transforms the daunting challenge oncologists face—analyzing an overwhelming amount of genetic, molecular, and clinical data in record time—into an opportunity. This advancement paves the way for tailored therapies that patients urgently require.

Mimicking a Multidisciplinary Team

What sets Exacta AI apart is its capability to operate like a multidisciplinary team of experts. Dr. Vineet Datta, Senior Director for Global Strategy and Business Development, explained, "The platform analyzes data in ways comparable to molecular biologists, pharmacologists, and clinical oncologists—but within mere minutes instead of days. With precise, evidence-based assessments, Exacta AI delivers highly accurate treatment recommendations."

Enhancing the Efficacy of Molecular Tumor Boards

Oncologists and tumor boards are increasingly confronted with an ever-expanding trove of research outputs, clinical data, and molecular insights—a challenge that is nearly unmanageable without technological assistance. Exacta AI converts this data overwhelm into structured, actionable insights and streamlines MTB workflows by providing:

• - Structured case analyses
• - Evidence-based therapy options
• - Clear rationales and implementation scenarios
• - Comparative cases with similar molecular and clinical characteristics

In a retrospective study involving 265 patients with therapy-resistant solid tumors that had no standard treatment options, Exacta AI successfully generated at least seven to ten therapy options (drug combinations) for 100% of patients. In stark contrast, conventional molecular profiling yielded a maximum of two treatment options for only 15% of patients.

Ready for Clinical Use

Exacta AI is fully operational, offering seamless integration with cancer centers and hospitals, alongside training, ongoing support, routine updates, and quality assurance. Datar Cancer Genetics (DCG) continues to lead the way in personalized oncology, utilizing comprehensive, precise cancer analyses to design tailored treatment strategies without the trial-and-error approach, ultimately enabling timely and accurate therapy decisions for patients globally.

For more information, visit datarpgx.de.

Datar Cancer Genetics operates CAP- and CLIA-accredited facilities in the UK and India, serving patients worldwide and pushing forward the realm of precision oncology.